These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 27036358)

  • 1. Tuberculosis--advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers.
    Wallis RS; Maeurer M; Mwaba P; Chakaya J; Rustomjee R; Migliori GB; Marais B; Schito M; Churchyard G; Swaminathan S; Hoelscher M; Zumla A
    Lancet Infect Dis; 2016 Apr; 16(4):e34-46. PubMed ID: 27036358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tuberculosis treatment and management--an update on treatment regimens, trials, new drugs, and adjunct therapies.
    Zumla A; Chakaya J; Centis R; D'Ambrosio L; Mwaba P; Bates M; Kapata N; Nyirenda T; Chanda D; Mfinanga S; Hoelscher M; Maeurer M; Migliori GB
    Lancet Respir Med; 2015 Mar; 3(3):220-34. PubMed ID: 25773212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies.
    Tiberi S; du Plessis N; Walzl G; Vjecha MJ; Rao M; Ntoumi F; Mfinanga S; Kapata N; Mwaba P; McHugh TD; Ippolito G; Migliori GB; Maeurer MJ; Zumla A
    Lancet Infect Dis; 2018 Jul; 18(7):e183-e198. PubMed ID: 29580819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tuberculosis clinical trial update and the current anti-tuberculosis drug portfolio.
    Palomino JC; Martin A
    Curr Med Chem; 2013; 20(30):3785-96. PubMed ID: 23862617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early Biomarkers and Regulatory Innovation in Multidrug-Resistant Tuberculosis.
    Wallis RS; Peppard T
    Clin Infect Dis; 2015 Oct; 61Suppl 3():S160-3. PubMed ID: 26409278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development.
    Poce G; Cocozza M; Consalvi S; Biava M
    Eur J Med Chem; 2014 Oct; 86():335-51. PubMed ID: 25173852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Host-Directed Therapies for Tackling Multi-Drug Resistant Tuberculosis: Learning From the Pasteur-Bechamp Debates.
    Zumla A; Maeurer M;
    Clin Infect Dis; 2015 Nov; 61(9):1432-8. PubMed ID: 26219693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical testing of new drugs for tuberculosis: current challenges.
    Lenaerts AJ; Degroote MA; Orme IM
    Trends Microbiol; 2008 Feb; 16(2):48-54. PubMed ID: 18182291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in the research of heterocyclic compounds as antitubercular agents.
    Yan M; Ma S
    ChemMedChem; 2012 Dec; 7(12):2063-75. PubMed ID: 23042656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Translating the Tuberculosis Research Agenda: Much Accomplished, but Much More to Be Done.
    Schito M; Maeurer M; Kim P; Hanna D; Zumla A
    Clin Infect Dis; 2015 Oct; 61Suppl 3(Suppl 3):S95-101. PubMed ID: 26409286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent therapeutic approaches for the management of tuberculosis: Challenges and opportunities.
    Patil K; Bagade S; Bonde S; Sharma S; Saraogi G
    Biomed Pharmacother; 2018 Mar; 99():735-745. PubMed ID: 29710471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Host Directed Therapies for Tuberculosis: Futures Strategies for an Ancient Disease.
    Palucci I; Delogu G
    Chemotherapy; 2018; 63(3):172-180. PubMed ID: 30032143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New treatment options for multidrug-resistant tuberculosis.
    Field SK; Fisher D; Jarand JM; Cowie RL
    Ther Adv Respir Dis; 2012 Oct; 6(5):255-68. PubMed ID: 22763676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis.
    Zumla A; Rao M; Dodoo E; Maeurer M
    BMC Med; 2016 Jun; 14():89. PubMed ID: 27301245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects.
    Zumla AI; Gillespie SH; Hoelscher M; Philips PP; Cole ST; Abubakar I; McHugh TD; Schito M; Maeurer M; Nunn AJ
    Lancet Infect Dis; 2014 Apr; 14(4):327-40. PubMed ID: 24670627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the development of new tuberculosis drugs and treatment regimens.
    Zumla A; Nahid P; Cole ST
    Nat Rev Drug Discov; 2013 May; 12(5):388-404. PubMed ID: 23629506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes.
    Lienhardt C; Vernon A; Raviglione MC
    Curr Opin Pulm Med; 2010 May; 16(3):186-93. PubMed ID: 20216421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges and opportunities in developing novel drugs for TB.
    Kaneko T; Cooper C; Mdluli K
    Future Med Chem; 2011 Sep; 3(11):1373-400. PubMed ID: 21879843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Not Available].
    Tiberi S; Buchanan R; Caminero JA; Centis R; Arbex MA; Salazar M; Potter J; Migliori GB
    Presse Med; 2017 Mar; 46(2 Pt 2):e41-e51. PubMed ID: 28256383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.